PMV Pharmaceuticals, Inc. — 2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report. PMV is a clinical-stage precision oncology company developing therapies targeting p53; it had no approved products or product revenue.
Financial results and liquidity
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $36.5 million | $23.9 million |
| General and administrative expense | $21.8 million | $11.0 million |
| Total operating expenses | $58.3 million | $34.9 million |
| Net loss | $57.8 million | $34.4 million |
| Net loss per share, basic and diluted | $1.28 | $2.40 |
| Cash used in operating activities | $46.6 million | $32.7 million |
Research and development spending increased mainly as PC14586 advanced in its Phase 1/2 trial. General and administrative expense rose with staffing, public-company costs, insurance, and facilities. Operating margins are not meaningful for this pre-revenue company.
At year-end, cash, cash equivalents, and marketable securities totaled $314.1 million, down from $361.4 million in 2020. Current assets were $301.3 million and current liabilities $12.2 million, yielding working capital of $289.1 million. The balance sheet reported no borrowings; operating lease liabilities totaled $11.2 million, including $0.4 million current. Accumulated deficit was $167.7 million.
Investing activities used $143.6 million, primarily reflecting purchases of marketable securities; financing activities provided $2.0 million, mainly from stock-option exercises. Cash operating expenditures were $46.6 million. Management expected year-end resources to fund planned operations through 2023, while the financial-statement note states that resources were adequate for at least twelve months from issuance; both estimates depend on assumptions and spending needs.
Business developments and outlook
- Lead candidate PC14586, an oral therapy designed to restore wild-type function to p53 Y220C, was in a Phase 1/2 clinical trial initiated in October 2020. The trial evaluates dose, safety, tolerability, biomarkers, and preliminary antitumor activity; the filing reported no clinical data.
- PC14586 received FDA Fast Track designation in October 2020. Management planned to seek tumor-agnostic accelerated approval if trial results support it, but the FDA may require additional studies or a narrower indication. Accelerated approval and a pivotal role for the Phase 1/2 trial are not assured.
- Other programs remained early stage: WIP1 was in lead optimization, while R282W and R273H programs were progressing toward lead optimization. Management expected increased research and development investment in 2022 and anticipated continued losses.
- The company reported preclinical activity for PC14586, including tumor regression in animal models and combination activity with anti-PD-1 therapy. These findings are not evidence of clinical benefit in humans.
Key risks, contingencies, and unusual items
- Clinical and regulatory uncertainty is substantial: the approach is novel, PC14586 is early in development, and the company had not completed a clinical trial or demonstrated efficacy or safety in patients.
- Risks include limited availability of patients with the target mutation, trial delays or disruption from COVID-19, reliance on third-party research and manufacturing providers, and the need for companion diagnostic development and approval.
- The company expects to need substantial additional capital over time. Future equity financing could dilute shareholders; debt or partnerships could impose restrictions or require surrendering rights.
- A new Princeton facility lease extends through 2032. The filing reports $11.2 million of recognized lease liabilities and approximately $20.4 million of future lease payments as of year-end; the new lease includes a $4.1 million buildout reimbursement expected in 2022.
- No material legal proceedings or supplier purchase commitments were reported as of the stated dates. Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting. The auditor identified R&D accruals and related prepaid expenses as a critical audit matter because estimates depend on vendor service progress.
Important facts for investors to verify
- Clinical-trial enrollment, safety, dose selection, response rate, and durability data for PC14586 as they become available.
- Whether FDA agrees with the proposed tumor-agnostic and accelerated-approval strategy, and whether additional trials or companion diagnostics will be required.
- Cash burn, investment maturities, and whether the stated runway through 2023 remains achievable as development spending rises.
- Progress and costs at the Princeton facility, including lease obligations and timing of the buildout reimbursement.
- Potential financing, dilution, manufacturing or supply interruptions, and the strength and scope of patent protection.